{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T21:23:47Z","timestamp":1649021027943},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/mjt.0b013e318197c59d","type":"journal-article","created":{"date-parts":[[2009,9,16]],"date-time":"2009-09-16T07:14:09Z","timestamp":1253085249000},"page":"379-384","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetics of Laropiprant and Glucuronide Metabolite in Patients with Severe Renal Insufficiency"],"prefix":"10.1097","volume":"16","author":[{"given":"Mark","family":"Stroh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larissa","family":"Wenning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Lin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Keshavarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norman Martin","family":"Lunde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eseng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Dishy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210202","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"15-Year mortality in coronary drug project patients: long-term benefit with niacin.","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R2-3-20210202","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11883-000-0096-y","article-title":"Niacin dosing: relationship to benefits and adverse effects.","volume":"2","author":"Capuzzi","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"R3-3-20210202","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R5-3-20210202","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.clpt.6100180","article-title":"Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.","volume":"81","author":"Lai","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"R6-3-20210202","first-page":"873","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D(2) receptor antagonist.","volume":"83","author":"Lai","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R7-3-20210202","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1124\/dmd.107.014696","article-title":"Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.","volume":"35","author":"Karanam","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R8-3-20210202","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1161\/01.CIR.0000095676.90936.80","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention.","volume":"108","author":"Sarnak","year":"2003","journal-title":"Circulation"},{"key":"R9-3-20210202","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.ajkd.2004.04.024","article-title":"Kidney disease as a risk factor for recurrent cardiovascular disease and mortality.","volume":"44","author":"Weiner","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R10-3-20210202","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1001\/archinte.166.17.1884","article-title":"Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control.","volume":"166","author":"Parikh","year":"2006","journal-title":"Arch Intern Med"},{"key":"R11-3-20210202","first-page":"91","article-title":"K\/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.","volume":"41","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R12-3-20210202","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins.","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"R13-3-20210202","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1177\/0091270007300264","article-title":"Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites.","volume":"47","author":"Menon","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R14-3-20210202","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1124\/dmd.106.011551","article-title":"Metabolism of MK-0524, a prostaglandin D-2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans.","volume":"35","author":"Dean","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"R15-3-20210202","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jchromb.2006.04.022","article-title":"Determination of a prostaglandin D-2 antagonist and its acyl glucuronide metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometric detection: a lack of MS\/MS selectivity between a glucuronide conjugate and a phase I metabolite.","volume":"837","author":"Schwartz","year":"2006","journal-title":"J Chromatogr B"},{"key":"R16-3-20210202","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-200909000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:40:48Z","timestamp":1618036848000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-200909000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e318197c59d","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}